These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 11826259)

  • 21. Question 2 Should a child with ADHD and epilepsy be given ritalin?
    Boyes C
    Arch Dis Child; 2010 Sep; 95(9):759-61. PubMed ID: 20716679
    [No Abstract]   [Full Text] [Related]  

  • 22. Growth disturbances in hyperkinetic children.
    Greenhill LL; Puig-Antich J; Halpern F; Sachar EJ; Rubinstein B; Chambers W; Fiscina B; Florea J
    Pediatrics; 1980 Jul; 66(1):152-4. PubMed ID: 7402783
    [No Abstract]   [Full Text] [Related]  

  • 23. Managing stimulant medication for attention-deficit/hyperactivity disorder.
    Wender EH
    Pediatr Rev; 2001 Jun; 22(6):183-90. PubMed ID: 11389305
    [No Abstract]   [Full Text] [Related]  

  • 24. Attention deficit and hyperactivity disorder, methylphenidate, and epilepsy.
    Tan M; Appleton R
    Arch Dis Child; 2005 Jan; 90(1):57-9. PubMed ID: 15613514
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risperidone effects in the presence/absence of psychostimulant medicine in children with ADHD, other disruptive behavior disorders, and subaverage IQ.
    Aman MG; Binder C; Turgay A
    J Child Adolesc Psychopharmacol; 2004; 14(2):243-54. PubMed ID: 15319021
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Medication options when treating children and adolescents with ADHD: interpreting the NICE guidance 2006.
    Harpin VA
    Arch Dis Child Educ Pract Ed; 2008 Apr; 93(2):58-65. PubMed ID: 18356307
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Growth deficits in children with attention deficit hyperactivity disorder.
    Spencer T; Biederman J; Wilens T
    Pediatrics; 1998 Aug; 102(2 Pt 3):501-6. PubMed ID: 9685453
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Stimulant use and trichotillomania.
    Martin A; Scahill L; Vitulano L; King RA
    J Am Acad Child Adolesc Psychiatry; 1998 Apr; 37(4):349-50. PubMed ID: 9549952
    [No Abstract]   [Full Text] [Related]  

  • 29. [Life-threatening heart failure caused by ADHD medication. Five case reports described].
    Wikström G; Kvidal P; Hagström E
    Lakartidningen; 2012 Nov 7-13; 109(45):2016-8. PubMed ID: 23240309
    [No Abstract]   [Full Text] [Related]  

  • 30. European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder.
    Coghill D; Banaschewski T; Lecendreux M; Soutullo C; Johnson M; Zuddas A; Anderson C; Civil R; Higgins N; Lyne A; Squires L
    Eur Neuropsychopharmacol; 2013 Oct; 23(10):1208-18. PubMed ID: 23332456
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The relationship between stimulant medication and tics.
    Golden GS
    Pediatr Ann; 1988 Jun; 17(6):405-6, 408. PubMed ID: 2898748
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Trichotillomania in Attention-Deficit/Hyperactivity Disorder Under Methylphenidate Treatment.
    Kara T; Akaltun İ
    J Clin Psychopharmacol; 2017 Aug; 37(4):484. PubMed ID: 28492426
    [No Abstract]   [Full Text] [Related]  

  • 33. Association between treatment with central nervous system stimulants and Raynaud's syndrome in children: a retrospective case-control study of rheumatology patients.
    Goldman W; Seltzer R; Reuman P
    Arthritis Rheum; 2008 Feb; 58(2):563-6. PubMed ID: 18240233
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term stimulant medication treatment of attention-deficit/hyperactivity disorder: results from a population-based study.
    Barbaresi WJ; Katusic SK; Colligan RC; Weaver AL; Leibson CL; Jacobsen SJ
    J Dev Behav Pediatr; 2014 Sep; 35(7):448-57. PubMed ID: 25180895
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevalence and characteristics of adolescents patients with co-occurring ADHD and substance dependence.
    Gordon SM; Tulak F; Troncale J
    J Addict Dis; 2004; 23(4):31-40. PubMed ID: 15339712
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [In process].
    Schoppmeyer M
    Med Monatsschr Pharm; 2017 Mar; 40(3):130. PubMed ID: 29952485
    [No Abstract]   [Full Text] [Related]  

  • 37. Attention deficit hyperactivity disorder, combined type: better executive function performance with longer-term psychostimulant medication.
    Vance AL; Maruff P; Barnett R
    Aust N Z J Psychiatry; 2003 Oct; 37(5):570-6. PubMed ID: 14511085
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Reaction on 'Follow-up of the MTAstudy in children with ADHD: what do the data tell us, and what not?'].
    Nieweg EH
    Tijdschr Psychiatr; 2010; 52(8):601-3; author reply 603-5. PubMed ID: 20698001
    [No Abstract]   [Full Text] [Related]  

  • 39. Side effects of methylphenidate and dexamphetamine in children with attention deficit hyperactivity disorder: a double-blind, crossover trial.
    Efron D; Jarman F; Barker M
    Pediatrics; 1997 Oct; 100(4):662-6. PubMed ID: 9310521
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dexamphetamine for obsessive-compulsive disorder.
    Woolley JB; Heyman I
    Am J Psychiatry; 2003 Jan; 160(1):183. PubMed ID: 12505824
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.